The balance of 2022 is 100 days, how many goals have been achieved by major pharmaceutical machinery companies at the beginning of the year?

【Pharmaceutical Network Industry News】Time flies, and the balance of 2022 is only 100 days left, so how much has the goal of major pharmaceutical equipment companies completed at the beginning of the year? At present, the plans and visions of many pharmaceutical machinery companies are steadily advancing, and some companies are sprinting hard to live up to every moment
.

The balance of 2022 is 100 days, how many goals have been achieved by major pharmaceutical machinery companies at the beginning of the year? Chutian Technology mentioned in a survey in April this year that this year's growth plan is to plan revenue and net profit growth of not less than 20%
compared with 2021.

The 2021 annual report shows that during the reporting period, the company achieved operating income of 5.
260 billion yuan and net profit of 566 million yuan
.

Judging from the data of the 2022 interim report, the company is moving towards the goal, achieving a total operating income of 2.
871 billion yuan in the first half of the year, an increase of 20% year-on-year; Achieved net profit attributable to the mother of 299 million yuan, an increase of 26.
7%
year-on-year.

Within 6 months, a total of 12 institutions have made predictions
for the 2022 annual performance of Chutian Technology.

It is predicted that the net profit in 2022 will be between 684 million and 915 million, with an average value of 700 million yuan, an increase of 23.
61%
over last year.

International business has become one of the important sources of income of Chutian Technology, and its international business includes all the business of German Romaco and the export business
of domestic main companies.

According to the 2021 annual report, the company's overseas operating income reached 1.
803 billion yuan, accounting for 34.
3%, and the export income of the domestic headquarters in 21 years was 480 million yuan
.

For the domestic headquarters export business, the company said at the 2021 annual performance briefing that the 22-year domestic headquarters export new orders target doubled compared with the previous year
.

That is to say, this year's Chutian headquarters export new order target is approaching 900 million
.

At the beginning of June, the company disclosed a record of investor relations activities that once again mentioned that the new order target for Chutian's headquarters planned export business this year doubled compared with 2021
.

Last year, due to the impact of the epidemic, the export business is not ideal, since the second half of last year, the company adjusted the overseas market development layout, in a number of countries and regions to build sales and service centers, localization operations, and vigorously promote market development, the company is confident to complete this year's planning
.

It is worth mentioning that the performance of ROMACO in the first half of the year is not satisfactory, and the semi-annual report shows that during the reporting period, Romaco achieved operating income of 531 million yuan in the first half of the year, down 23.
34% from the same period last year, and the net profit loss was 47.
53 million yuan, down 405.
08%
from the same period last year.

In this regard, the company said in the reception of the agency to ask questions, the current ROMACO orders in hand are sufficient, and according to the situation in previous years, ROMACO's performance in the second half of the year is better than the first half of the year, and it is confident to achieve the performance commitment of mergers and acquisitions
throughout the year.

According to the Performance Commitment Compensation Agreement signed by both parties when Chutian Technology acquired ROMACO, Romaco's forecast net profit in 2022 will not be less than 9 million euros
.

Whether Chutian can complete this goal in the second half of this year is worthy of attention
.

In addition to Chutian Technology, Dongfulong, as a domestic pharmaceutical machine head enterprise, is also moving towards a farther goal
.

In the first half of 2022, the company achieved operating income of 2.
427 billion yuan, an increase of 34.
11% year-on-year; The net profit attributable to the shareholders of the listed company was 403 million yuan, an increase of 18.
33%
year-on-year.

Within 6 months, a total of 13 institutions have made predictions for Dongfulong's 2022 annual performance, predicting that the average net profit in 2022 will be 1.
050 billion yuan, an increase of 26.
82%
over last year.

According to the 2021 annual report, Dongfulong achieved revenue of 4.
192 billion yuan and net profit attributable to shareholders of listed companies of 828 million yuan
.

The pharmaceutical equipment industry is located in the upstream of the pharmaceutical industry chain, supported by favorable policies and driven by the expansion of downstream pharmaceutical industry demand, and the transformation and upgrading of the industry has accelerated
.

In this context, leading enterprises such as Chutian and Dongfulong are increasing their market share this year by increasing R&D investment, expanding production capacity, and improving the quality and performance of equipment
.

Small and medium-sized enterprises have insufficient advantages in technology and research and development, and the performance growth rate is relatively slower than that of head enterprises
.

For example, Canaan Technology achieved revenue of less than 500 million yuan in the first half of this year, only 493.
8 million yuan, an increase of 14.
33% year-on-year; Net profit was 42.
3643 million yuan, an increase of 12.
63%
year-on-year.

Aoxing Life Science and Technology achieved total revenue of 1.
1 billion yuan, an increase of 29.
1% year-on-year; Profit attributable to owners of the company was RMB45.
84 million, down 78.
96%
year-on-year.

From the perspective of the development prospects of the entire industry, with the intensification of aging and the continuous upgrading of consumption, the demand for innovative drugs, biological drugs and pharmaceutical outsourcing continues to expand, bringing huge
development space to the pharmaceutical equipment industry.

Some data predict that the size of China's pharmaceutical equipment market will reach 200 billion yuan
by 2025.

New opportunities have arrived
.

The industry believes that in the domestic market, domestic pharmaceutical machinery enterprises should continue to increase research and development of high-end products, continuously improve product quality and performance, and meet the new needs of
the transformation of the pharmaceutical industry.

In addition, in overseas markets, domestic pharmaceutical machine manufacturers can also increase their layout and continue to exert efforts, seize domestic substitution and export opportunities, and continuously increase their share
in domestic and foreign markets.

Disclaimer: Under no circumstances does the information herein or the opinions expressed in this article constitute investment advice
to any person.